CD161 is a type II transmembrane glycoprotein, also known as NKR-P1A, that is expressed as a 40-44 kD homodimer. It is a member of the C-type lectin superfamily. CD161 is expressed on a majority of NK cells, NKT cells, and subsets of peripheral T cells and CD3+ thymocytes. It has been reported that Th17 cells are a subpopulation of CD4+CD161+CCR6+ cells. While the biological function of CD161 is not clear, it has been suggested to serve either as a stimulatory receptor or to inhibit NK cell-mediated cytotoxicity and cytokine production. LLT-1 (lectin-like transcript-1, also named as osteoclast inhibitory lectin or CLEC2D) is the ligand of CD161.
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.
Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.
This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes
Additional reported applications (for the relevant formats) include: inhibition of cytokine production and Western blotting under nonreducing conditions.
Application References
(PubMed link indicates BioLegend citation)
Gumß M, et al. 2004. Blood 104:3664.
Exley M, et al. 1998. J. Exp. Med. 188:867.
Marquez C, et al. 1998. Blood 91:2760.
Product Citations
Lamichhane R et al. 2019. Cell Rep. 28(12):3061-3076 . PubMed
Ravindran A, et al. 2018. Front Immunol. 9:2193. PubMed
Cella M, et al. 2019. Nat Immunol. 1.513888889. PubMed
Type II glycoprotein, 40-44 kD homodimer, C-type lectin superfamily
Distribution
NK cells, T subset, subset of CD3+ thymocytes
Ligand/Receptor
LLT-1 (Lectin-like transcript-1)
Cell Type
NK cells, T cells, Thymocytes
Biology Area
Cell Biology, Immunology, Innate Immunity, Signal Transduction
Molecular Family
CD Molecules
Antigen References
1. Takahashi T, et al. 2006. J. Immunol. 176:211.
2. Cosmi L, et al. 2008. J. Exp. Med. 205:1903.
3. Aldemir H, et al. 2005. J. Immunol. 175:7791.
4. Rosen DB, et al. 2008. J. Immunol. 180:6508.
This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.
